Public Health
Study Overview
The IPAT trial is a study aimed at preventing Alzheimer’s disease by examining how lowering high systolic blood pressure (SBP) affects brain health in older adults. This study will last for 2 years and is currently recruiting participants.
Key Details
- Study Duration: October 2022 – September 2025
- Participants Needed: 180 individuals aged 60-85 with SBP of 130mmHg or higher
- Exclusions: Individuals with major cerebrovascular diseases, diagnosed Alzheimer’s disease, or those unable to undergo MRI
Recruitment Methods
The study uses various methods to recruit participants, including:
- Hospital databases
- Virtual sources
- Referrals
- Community outreach
Recruitment Results
From October 2022 to December 2023:
- Total Potential Participants: 718
- Scheduled Consent Appointments: 77 (10.7%)
- Randomized Participants: 23 (3.2%)
The most successful recruitment source was hospital databases, yielding:
- 67% of total responses
- 68% of consent visits
- 56% of randomizations
Conclusions
The IPAT study successfully recruited participants mainly through hospital databases. However, more effort is needed in virtual resources and community outreach to meet enrollment goals.
Importance of Clinical Trials
Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, helps integrate clinical standards and research into a user-friendly resource for healthcare providers.
Streamlining Healthcare
In today’s healthcare landscape, efficiency is key. Our mobile apps facilitate:
- Scheduling
- Monitoring treatments
- Telemedicine services
This makes patient care management easier and expands digital services.
Enhancing Patient Outcomes
By leveraging AI, clinics can improve workflows, enhance patient outcomes, and reduce reliance on paper processes. Discover more at aidevmd.com.
